List of Excipients in Branded Drug CLEOCIN PHOSPHATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CLEOCIN PHOSPHATE	clindamycin phosphate	0009-0302	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	CLEOCIN PHOSPHATE	clindamycin phosphate	0009-0302	EDETATE DISODIUM
Pharmacia & Upjohn Company LLC	CLEOCIN PHOSPHATE	clindamycin phosphate	0009-0302	HYDROCHLORIC ACID

# Cleocin Phosphate Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Cleocin Phosphate is the clindamycin phosphate prodrug used in parenteral, topical, and vaginal formulations. Its commercial opportunity is no longer based on primary-molecule exclusivity. The strongest opportunities are formulation quality, preservative strategy, tolerability, supply reliability, device presentation, and differentiated generic or branded-generic positioning. Injectable products require the highest control of excipient safety, pH, particulate burden, and container compatibility. Topical and vaginal products offer more room for excipient-led differentiation.

What is Cleocin Phosphate and which dosage forms use it?

Cleocin Phosphate contains clindamycin phosphate, a water-soluble ester of clindamycin. It is hydrolyzed in vivo to active clindamycin. The product has been used across systemic, topical, and intravaginal delivery routes.

Product category	Active ingredient	Primary commercial function	Key excipient issues
Injection	Clindamycin phosphate	Systemic antibacterial therapy	Benzyl alcohol, pH control, chelation, sterility, container compatibility
Topical solution	Clindamycin phosphate	Acne treatment	Alcohol level, drying, irritation, solubilization
Topical gel	Clindamycin phosphate	Acne treatment	Carbomer rheology, neutralization, spreadability, preservative system
Topical lotion	Clindamycin phosphate	Acne treatment	Emulsion stability, skin feel, preservative performance
Vaginal cream	Clindamycin phosphate	Bacterial vaginosis	Emulsion structure, vaginal tolerability, oil compatibility, applicator delivery

The regulatory and commercial strategy differs materially by route. Injectable products are constrained by parenteral safety requirements. Dermatology products permit more formulation flexibility but face intense generic competition. Vaginal products may support differentiated delivery and tolerability claims, but excipient changes can affect local exposure and product performance.

What excipients are used in Cleocin Phosphate injection?

The Cleocin Phosphate injection formulation uses a relatively compact excipient system. FDA labeling identifies benzyl alcohol as a preservative, disodium edetate as a chelating agent, and sodium hydroxide for pH adjustment. The product is supplied as a sterile aqueous solution containing clindamycin phosphate at multiple concentrations, including 150 mg/mL presentations in historical labeling.[1]

Excipient	Function	Commercial and technical relevance
Benzyl alcohol	Antimicrobial preservative	Supports multidose or preserved presentations but creates neonatal and vulnerable-patient restrictions
Disodium edetate	Chelator	Controls trace-metal catalyzed degradation and may improve solution stability
Sodium hydroxide	pH adjustment	Establishes target pH and affects stability, compatibility, and injection tolerability
Water for injection	Vehicle	Determines osmolality, concentration, and container-fill requirements

The formulation is designed for intramuscular or intravenous administration. Intravenous administration requires dilution in compatible infusion solutions and controlled infusion rates because rapid administration has been associated with serious cardiopulmonary reactions. The label also identifies excipient and presentation considerations for neonatal use, particularly the presence of benzyl alcohol.[1]

Why is benzyl alcohol commercially important?

Benzyl alcohol is the most commercially significant excipient in the injectable product. It provides antimicrobial protection, but it can restrict use in neonates and may affect hospital formulary preferences for vulnerable populations. A preservative-free presentation could create a targeted opportunity for neonatal, intensive-care, or high-risk patient settings if stability, container closure, and microbial-control requirements can be demonstrated.

A preservative-free strategy would require more than removing benzyl alcohol. The sponsor would need to establish:

• Sterility assurance through container-closure validation.
• In-use stability after vial entry or dose withdrawal.
• Compatibility with infusion systems and transfer devices.
• Particulate and visible-particle control.
• Stability across the intended storage range.
• A clear regulatory rationale for the new presentation.

The commercial value would depend on whether hospitals pay for the reduced preservative burden. A single-dose, preservative-free vial may have stronger clinical utility than a multidose preserved format, but it could increase packaging and manufacturing costs.

What excipient strategy is strongest for injectable clindamycin phosphate?

The strongest injectable strategy is conservative formulation improvement rather than aggressive excipient substitution.

1. Preservative-free single-dose presentation

A preservative-free product could target neonatal and critical-care use. It would require a robust single-dose package, such as a ready-to-use vial or prefilled syringe, with validated sterility and low extractables.

2. Ready-to-administer dilution

Hospitals may value products that reduce manipulation. Opportunities include:

• Standardized infusion bags.
• Pharmacy-ready diluted presentations.
• Premeasured doses.
• Compatible closed-system transfer formats.

The relevant IP would more likely arise from container closure, concentration, packaging, or device design than from the active ingredient.

3. Low-extractable packaging

Clindamycin phosphate injection is an aqueous, high-concentration product. Elastomer compatibility, adsorption, leachables, and particulate formation should be assessed for vial stoppers, syringes, infusion bags, and administration sets. A low-extractable package may support a hospital-quality differentiation strategy even if it does not create broad patent protection.

4. Stability and supply-chain improvement

A formulation with improved room-temperature stability, reduced light sensitivity, or broader shipping conditions could reduce pharmacy waste. The opportunity is strongest where hospitals experience stockouts, short dating, or high product wastage.

What excipients are used in Cleocin Phosphate topical products?

Cleocin Phosphate topical products use excipients selected for solubilization, evaporation, viscosity, skin feel, and microbial protection. FDA labeling for clindamycin phosphate topical products identifies vehicles that may include alcohol, propylene glycol, water, carbomer, methylparaben, and neutralizing agents, depending on the dosage form.[2,3]

Topical format	Excipient strategy	Main patient or manufacturing issue
Solution	Alcohol-water or hydroalcoholic vehicle	Dryness, stinging, flammability, rapid evaporation
Gel	Carbomer or equivalent polymer system	Viscosity, pH, tack, phase behavior
Lotion	Emulsion or suspension vehicle	Physical stability, preservative robustness, skin feel
Foam or aerosol	Volatile propellant and surfactant system	Device complexity, flammability, cold sensation

Topical clindamycin is used primarily for acne. The commercial field includes generic solutions, gels, lotions, combinations with benzoyl peroxide, and products paired with retinoids. This makes excipient performance important, but it also limits pricing power unless the product improves tolerability, adherence, or convenience.

What topical excipient opportunities remain?

The most credible opportunities are:

• Lower-irritancy hydroalcoholic systems.
• Reduced tack and faster drying.
• Noncomedogenic emulsion systems.
• Improved spreadability with lower residue.
• Packaging that limits contamination.
• Polymer systems that maintain viscosity across temperature variation.
• Lower-preservative or preservative-free formats where microbiological control permits.
• Combination-compatible vehicles for clindamycin and benzoyl peroxide or retinoids.

A low-irritation vehicle may be commercially relevant because alcohol and propylene glycol can contribute to dryness or burning in acne patients. The formulation must preserve clindamycin phosphate solubility and chemical stability while avoiding excessive occlusion.

What excipients are used in clindamycin phosphate vaginal cream?

Clindamycin phosphate vaginal cream is an oil-in-water emulsion system. Public prescribing information identifies excipients including mineral oil, polysorbate 60, stearic acid, cetostearyl alcohol, glyceryl monostearate, sorbitan monostearate, propylene glycol, and water, with formulation details varying by manufacturer and product presentation.[4]

Excipient class	Function in vaginal cream
Mineral oil	Emollient and oil-phase vehicle
Fatty alcohols and stearic acid	Consistency, structure, and emulsion support
Glyceryl monostearate	Emulsification and texture
Polysorbate and sorbitan esters	Emulsion stabilization
Propylene glycol	Humectancy and co-solvency
Purified water	Continuous phase

The most important commercial constraint is compatibility with latex contraceptive products. The Cleocin vaginal cream label warns that the cream base can weaken latex or rubber products, including condoms and diaphragms, for a specified period after treatment.[4] That warning creates a direct opportunity for a non-oily or lower-lipid vehicle, provided the new formulation maintains equivalent drug delivery and local tolerability.

Can a non-oily vaginal vehicle create a differentiated product?

Yes. A water-based or polymer-based vaginal formulation could address:

• Latex compatibility.
• Reduced leakage.
• Lower residue.
• Improved patient comfort.
• Less dependence on oil-phase structure.
• More convenient dosing and applicator delivery.

The technical challenge is maintaining clindamycin phosphate solubility, dose uniformity, rheology, vaginal retention, and microbiological quality. A polymeric gel may improve residence time but can increase residue or affect patient acceptance. A lower-viscosity liquid may improve delivery but increase leakage.

What formulations are protected by patents?

Legacy Cleocin Phosphate products are unlikely to retain meaningful primary-compound exclusivity. Commercial protection is more likely to arise from:

1. Specific excipient ratios.
2. Viscosity or rheology ranges.
3. Preservative-free presentations.
4. Container-closure systems.
5. Applicator designs.
6. Combination products.
7. Controlled-release or extended-residence systems.
8. Manufacturing controls that produce a defined particle, droplet, or emulsion profile.

Patent value depends on claim scope, prosecution history, expiration, enforceability, and whether the claims cover commercially necessary features. A narrow patent on a particular polymer concentration or applicator may be easy to design around. A patent covering a clinically meaningful combination of vehicle composition, drug release, and delivery device has stronger commercial relevance.

The highest-value formulation claims would connect composition to measurable performance, such as:

• Equivalent or improved local exposure.
• Reduced irritation.
• Improved retention.
• Latex compatibility.
• Reduced microbial contamination.
• Improved physical stability.
• Reduced dose variability.

When does Cleocin Phosphate lose exclusivity?

The active ingredient has been off patent for many years, and multiple generic clindamycin phosphate products have entered the U.S. market. FDA regulatory exclusivity is therefore not the principal barrier to entry for standard injectable, topical, or vaginal products.

Exclusivity category	Current commercial significance
New chemical entity exclusivity	Expired
Basic composition-of-matter patent	Expired or commercially irrelevant
Standard formulation patents	Mostly legacy or product-specific
Method-of-use patents	Potentially relevant only for narrow indications
Pediatric exclusivity	Product- and indication-specific; not a broad barrier
Orphan exclusivity	Not generally relevant to standard clindamycin products
Device or packaging patents	Potentially relevant to differentiated presentations

The controlling date for a particular generic product is not the historic Cleocin launch date. It is the expiration or enforceability of any listed formulation, method-of-use, or device patent associated with the reference product, together with FDA approval requirements.

What is the Orange Book status of Cleocin Phosphate?

The Orange Book identifies patents and regulatory exclusivities associated with approved reference products. Standard clindamycin phosphate products may have different listing histories depending on dosage form, sponsor, and reference-product designation.[5]

For a commercial diligence review, the relevant questions are:

• Is the exact reference product listed?
• Are any patents currently listed?
• Do listed patents cover the dosage form, formulation, or method of use?
• Are the patents expired, delisted, or subject to an FDA listing dispute?
• Does the generic applicant need a Paragraph IV certification?
• Is a 30-month stay possible under the Hatch-Waxman framework?

Because Orange Book records change, the exact status must be assessed by product identifier and dosage form. The relevant patent risk is likely higher for a novel combination, delivery device, or modified formulation than for a conventional clindamycin phosphate injection.

Which companies are challenging or competing with Cleocin Phosphate?

Competition includes established generic manufacturers, hospital-focused suppliers, specialty dermatology companies, and developers of alternative acne or bacterial-vaginosis treatments.

Injectable competition

Injectable clindamycin phosphate competes on:

• Contract reliability.
• Concentration and vial size.
• Preservative profile.
• Shortage performance.
• Hospital contracting.
• Ready-to-administer packaging.
• Unit cost.

The leading commercial risk is commoditization. A new entrant needs either a lower total cost of ownership or a supply and presentation advantage.

Topical competition

Topical clindamycin competes with:

• Generic clindamycin phosphate solution, gel, and lotion.
• Clindamycin and benzoyl peroxide combinations.
• Clindamycin and tretinoin products.
• Benzoyl peroxide monotherapy.
• Topical retinoids.
• Newer non-antibiotic acne products.

Antimicrobial-stewardship concerns limit the long-term strategic value of topical antibiotic monotherapy. Combination products and shorter treatment courses may have stronger market relevance than an undifferentiated clindamycin product.

Vaginal competition

Vaginal clindamycin competes with metronidazole products, oral and vaginal formulations, secnidazole, and other bacterial-vaginosis treatments. Patient preference, recurrence, odor, leakage, applicator design, and latex compatibility can influence product selection.

How strong is the patent estate for Cleocin Phosphate?

The patent estate for conventional Cleocin Phosphate products is weak from a basic-molecule perspective and potentially moderate for specialized formulations.

IP layer	Relative strength	Commercial assessment
Clindamycin phosphate molecule	Low	Mature generic active ingredient
Conventional aqueous injection	Low	Limited formulation complexity
Preservative-free injection	Moderate	Potential composition and package claims
Ready-to-administer presentation	Moderate	Device and packaging claims may apply
Topical gel vehicle	Low to moderate	Crowded and design-around risk is high
Vaginal non-oily vehicle	Moderate	Latex compatibility and retention may support differentiation
Applicator or delivery system	Moderate	Valuable if linked to dose uniformity or usability
Combination products	Moderate to high	Broader clinical and formulation claim possibilities

Patent strength improves when claims require a difficult-to-reproduce formulation property and when that property has commercial or clinical value. A claim limited to common excipients at ordinary concentrations is less defensible than a claim covering a defined composition, process, and performance result.

What manufacturing and IP barriers affect new entrants?

The main barriers are technical and regulatory rather than molecular IP.

Injectable manufacturing barriers

• Sterile solution processing.
• High-concentration drug loading.
• Control of particulates and endotoxin.
• Container-closure integrity.
• Extractables and leachables.
• Preservative assay and uniformity.
• Compatibility with infusion materials.
• Validation of aseptic filling.

Topical manufacturing barriers

• Polymer hydration and deaeration.
• pH and viscosity control.
• Emulsion particle-size distribution.
• Microbial limits and preservative effectiveness.
• Fill-weight uniformity.
• Tube or pump compatibility.
• Stability under freeze-thaw and elevated-temperature conditions.

Vaginal manufacturing barriers

• Emulsion stability.
• Applicator dose delivery.
• Vaginal retention and leakage control.
• Local irritation testing.
• Compatibility with contraceptive materials.
• Microbial quality over shelf life.
• Uniformity of drug concentration across the batch.

A formulation patent is most valuable when it protects a manufacturing process that is difficult to reproduce at commercial scale. Process know-how, supplier qualification, and validated excipient grades may create practical barriers even when patent protection is limited.

What generic launch risks exist for Cleocin Phosphate?

Generic launch risk differs by dosage form.

Launch type	Risk level	Principal risk
Conventional injection	Moderate	Price erosion and hospital contracting
Preservative-free injection	Moderate	Clinical adoption and manufacturing cost
Topical solution	High	Crowded generic market
Topical gel	High	Substitution and low differentiation
Topical combination	Moderate	Regulatory complexity and clinical positioning
Vaginal cream	Moderate	Latex warning, patient preference, and alternative therapies
Novel vaginal gel or device	Moderate to high	Clinical equivalence and delivery performance

Paragraph IV risk is generally limited for legacy, unpatented standard products. It becomes material where a reference product has active listed patents covering a specific formulation, combination, or delivery system. A generic applicant may instead use Paragraph III certification, a section viii statement for method-of-use patents, or a design-around formulation, depending on the Orange Book record and proposed label.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target Cleocin Phosphate-related products through higher-value grades rather than commodity volume alone.

High-potential excipient categories

• Low-endotoxin and low-bioburden parenteral excipients.
• Preservative systems suitable for sensitive injectable products.
• Functional polymers for topical gels.
• Noncomedogenic emollients.
• Low-irritancy solubilizers.
• Latex-compatible vaginal cream bases.
• Mucoadhesive polymers.
• Low-extractable packaging components.
• Preservative efficacy enhancers.
• Ready-to-use formulation platforms.

The most attractive opportunity is a platform that can be used across multiple clindamycin dosage forms or across broader anti-infective portfolios. A supplier that offers formulation support, regulatory documentation, compendial compliance, and validated manufacturing data has stronger pricing leverage than a supplier selling an interchangeable commodity.

How does Cleocin Phosphate compare with other mature antibiotics?

Factor	Cleocin Phosphate	Metronidazole vaginal products	Generic beta-lactam injections
Active-ingredient maturity	Very high	Very high	Very high
Excipient differentiation	Moderate	Moderate	Moderate
Sterile manufacturing burden	High for injection	Lower for vaginal products	High
Topical opportunity	Established acne market	Limited topical overlap	Limited
Device opportunity	Moderate	Moderate	Moderate
Antimicrobial-stewardship pressure	High	High	High
Price competition	High	High	High
Best commercial angle	Delivery, tolerability, supply reliability	Convenience and recurrence management	Availability and hospital economics

Cleocin Phosphate is more commercially attractive as a differentiated delivery platform than as a conventional generic antibiotic. The strongest candidates are preservative-free injectable products, lower-irritancy topical systems, and latex-compatible vaginal formulations.

Key Takeaways

• Cleocin Phosphate is a mature clindamycin phosphate product with limited value from basic-molecule exclusivity.
• The main excipient opportunities are dosage-form specific.
• Injectable differentiation centers on preservative-free formats, container compatibility, sterility, and ready-to-administer delivery.
• Topical differentiation depends on reduced irritation, improved skin feel, polymer performance, and combination compatibility.
• Vaginal formulations have a clear opportunity to address the latex-weakening warning associated with oil-containing cream bases.
• Standard generic products face high price and substitution pressure.
• The strongest formulation patents would link excipient composition to measurable performance and clinical utility.
• Manufacturing know-how and validated supply chains may be more important than legacy composition patents.
• Orange Book and Paragraph IV analysis must be performed against the exact reference product and dosage form.
• Excipient suppliers have the greatest opportunity in functional polymers, low-irritancy vehicles, preservative systems, and low-extractable packaging.

FAQs

Can benzyl alcohol be removed from Cleocin Phosphate injection?

Yes, a preservative-free presentation is technically possible, but it would require a new formulation and package strategy with validated sterility, container closure, in-use stability, and regulatory support.

Is a clindamycin phosphate topical gel patentable?

A conventional gel is unlikely to provide broad protection by itself. Patentability improves when the formulation has a defined polymer system, measurable stability or tolerability benefit, and a non-obvious manufacturing process.

Can vaginal clindamycin cream be reformulated to preserve latex compatibility?

Yes. A water-based, polymeric, or otherwise lower-lipid vehicle could target latex compatibility, but the sponsor would need to demonstrate equivalent drug delivery, local safety, stability, and dose uniformity.

Does clindamycin phosphate require a biosimilar pathway?

No. Clindamycin phosphate is a small-molecule drug. Follow-on products use the abbreviated new drug application pathway rather than the biosimilar pathway.

What is the best commercial entry point for a new Cleocin Phosphate product?

The strongest entry points are a preservative-free injectable, a ready-to-administer hospital presentation, a lower-irritancy topical vehicle, or a latex-compatible vaginal delivery system. A conventional generic solution or cream has weaker differentiation potential.

References

1. U.S. Food and Drug Administration. (n.d.). Cleocin phosphate injection prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (n.d.). Cleocin T topical solution prescribing information. Pfizer Laboratories.

3. U.S. Food and Drug Administration. (n.d.). Clindamycin phosphate topical gel prescribing information. FDA labeling database.

4. U.S. Food and Drug Administration. (n.d.). Cleocin vaginal cream prescribing information. Pfizer Laboratories.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book